Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Tipranavir (Aptivus)
Conference Citations Archives

 3rd IAS Conference
 12th CROI
6th International Wkshop of Clinical HIV
 44th ICAAC
 XV International AIDS Conference
 2nd IAS Conference on HIV and Pathogenesis
 XII International HIV Drug Resistance Workshop
9th CROI
 41 ICAAC
XIV International AIDS Conference
 1st AS Conference on HIV and Pathogenesis
 		  
Tipranavir Conference Main Page New/Noteworthy Home Page      

Last Update:  August 27, 2007 
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
3rd IAS Conference on HIV and Pathogenesis
 
  • POSTER
         Tipranavir/ritonavir Demonstrates Superior Immunological Response  to Comparator
    Protease Inhibitors in a PI-Experienced Population with Advanced Disease
         C Hicks, B Grinstzejn. P Cahn, et al
    PDF Poster
  • POSTER
         Tipranavir/ritonavir Demonstrates Superior Treatment Response to Lopinavir,
    Amprenavir, and Saquinavir in PI-Experienced Patients from the TPV RESIST-1
    and RESIST-2 Disease
    A Lazarrin, G Mukwaya., N Clumek, et al 
     PDF Poster
  • Binding energetics analysis shows a unique response of tipranavir to HIV-1 protease mutations
    associated with drug resistance
    Muzammil S., Kang L.-W., Armstrong A.A, et al
    Abstract
  • A Long-Term Open-Label Rollover Trial Assessing the Safety and Tolerability of Combination
    Tipranavir and Ritonavir (TPV/r) Use in HIV-1–Infected Patients
    Pierone G., Drulak M., Arasteh K., et al
    Abstract
  • The Pharmacokinetics (PK) of Single-dose and Steady-state Tipranavir/Ritonavir (TPV/r) 500
    mg/200 mg in Subjects with Mild or Moderat.e Hepatic Impairment
    Cooper C., van Heeswijk R., Bilodeau M., et al
    Abstract
  • Tipranavir/ritonavir (TPV/r) 500 mg/200 mg BID drives week 24 viral load (VL) below 400
    copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced
    HIV+ patients.
    Valdez H., McCallister S., Kohlbrenner V., Mayers D.
    Abstract
  • Is predicted susceptibility to tipranavir/ritonavir (TPV/r) in treatment-experienced patients
    better than for other PI-boosted regimens ?
    Boulmé R., Gonzalez D., Struck D., et al
    Abstract
  • An Open-Label Steady State Investigation of the Pharmacokinetics (PK) of Tipranavir (TPV)
    and Ritonavir (RTV) and their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy
    Volunteers
    Nwando O., Themba B.
    Abstract
    •